Actively Recruiting
Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer
Led by Kong Fanming · Updated on 2025-06-24
405
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
Sponsors
K
Kong Fanming
Lead Sponsor
M
Ministry of Science and Technology of the People´s Republic of China
Collaborating Sponsor
AI-Summary
What this Trial Is About
Postoperative immunoadjuvant therapy has been proven to significantly reduce the risk of recurrence after resectable NSCLC, and has become a new standard of postoperative adjuvant therapy for stage II-III NSCLC. Immunotherapy faces challenges such as immune resistance, heterogeneity of biomarker expression, and limitation of immune-suitable population. How to reduce the rate of recurrence and metastasis after surgery, enhance the therapeutic effect of immunotherapy, and then prolong the survival period and improve the quality of life, has become an urgent problem facing the current clinical. Based on the standards of evidence-based medicine, this study for the first time carried out a large sample, multi-center, randomized parallel controlled clinical study to obtain high-quality clinical evidence of the effectiveness and safety of electro-acupuncture and Zilongjin tablet synergic treatment, and formed a standard treatment plan of traditional Chinese medicine.
CONDITIONS
Official Title
Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with stage I, IIA, or IIB (N2) non-small cell lung cancer by pathology or cytology after surgery
- Negative for driver mutations
- Received 1 to 4 cycles of postoperative adjuvant chemotherapy
- Meet two qi syndrome of traditional Chinese medicine diagnosis
- Aged 18 to 80 years old
- Expected to live more than 6 months
- ECOG performance status of 0 to 2
- Willing to accept the treatment and able to adhere well
You will not qualify if you...
- History of other malignant tumors within the past 5 years
- Serious heart, liver, or kidney damage or other serious complications
- Patients with R1 or R2 resection needing postoperative adjuvant radiotherapy
- Mental disorders
- Multiple drug allergies or allergic constitution
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Tianjin, China, 300381
Actively Recruiting
Research Team
F
Fanming Kong Director of Oncology Department, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here